The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | Characterization of exceptional responders to ASCT in multiple myeloma
Vincent Rajkumar
• 6 Dec 2018
The identification of those who are likely to response to a certain therapy is invaluable. Here, Vincent Rajkumar, MD, of the Mayo Clinic, Rochester, MN, discusses the characterization of exceptional responders to autologous stem cell transplantation in multiple myeloma. This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
